OMPI Share Price

Open 23.99 Change Price %
High 24.03 1 Day -0.01 -0.04
Low 23.98 1 Week 0.00 0.00
Close 23.98 1 Month 0.00 0.00
Volume 241671 1 Year 0.00 0.00
52 Week High 9.36
52 Week Low 0.00
OMPI Important Levels
Resistance 2 24.03
Resistance 1 24.01
Pivot 24.00
Support 1 23.95
Support 2 23.93
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Obagi Medical Products, Inc. (NASDAQ: OMPI)

OMPI Technical Analysis 5
As on 25th Apr 2013 OMPI Share Price closed @ 23.98 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.63 & Strong Buy for SHORT-TERM with Stoploss of 18.21 we also expect STOCK to react on Following IMPORTANT LEVELS.
OMPI Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
OMPI Other Details
Segment EQ
Market Capital 211049248.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
OMPI Address
OMPI
N/A
OMPI Latest News
Interactive Technical Analysis Chart Obagi Medical Products, Inc. ( OMPI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Obagi Medical Products, Inc.
OMPI Business Profile
Obagi Medical Products, Inc. (Obagi) is a specialty pharmaceutical company that develops, markets and sells, and is a provider of, topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Obagi systems and products are designed to prevent and improve the common and visible skin disorders in adult skin, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Obagi sells its products through a direct sales force in the United States and internationally through distribution partners in over 43 countries across North America, Central America, Europe, the Middle East and Asia. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc.